CRDF - Shares of Cardiff Oncology Inc. (CRDF) Exceed 52-Week High
Shares of Cardiff Oncology Inc. (NASDAQ:CRDF) traded today at $25.50, eclipsing its 52-week high. This new high was reached on above average trading volume as 52.1 million shares traded hands, while the average 30-day volume is approximately 637,000 shares.
In the past 52 weeks, Cardiff Oncology Inc. share prices are bracketed by a current low of $0.90 and a high of $10.24 and is now at $2.42.
Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.
Cardiff Oncology Inc. has overhead space with shares priced $2.42, or 4.0% below the average consensus analyst price target of $2.52.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer